SK Life Science is encouraging patients beetling down the long and winding road toward seizure-free life to switch gears. In a new nationwide direct-to-consumer ad, the Xcopri manufacturer asks partial-onset seizure patients to consider switching to a new treatment. More:
read morePresident Donald Trump’s recent Executive Order on drug prices applies to “all brand products across all markets that do not currently have generic or biosimilar competition,” the HHS said in a Tuesday press release. More: All branded drugs not facing
read moreFresh off taking the top spot in an annual survey of how patient groups around the world view major drugmakers, ViiV Healthcare has clinched the No. 1 slot in a U.S.-specific version of the survey, too. More: ViiV Healthcare retakes
read moreWith the FDA approval of the first blood-based test to help diagnose Alzheimer’s disease, Eisai and Biogen’s acceleration plan for Leqembi has been set in motion. But bending the Leqembi sales curve may still take time, a Mizuho analyst argued.
read more
Regulator confirms safety and efficacy of new treatment option for patient More: MHRA approves guselkumab for Crohn’s disease and ulcerative colitis Source: News
read more
Biotech spin-off targets fibrosis, neoplasm and neovascularization More: Massalia Therapeutics launches to advance novel treatments for complex conditions Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals